Neurobiology Research <a href='https://brc.riken.jp/mus/pcr00169'>Genotyping protocol -PCR-</a> Tnc(-/-)同士の兄妹交配。繁殖効率はA。実験群作出にはB6/N との交配必要。繁殖効率はB. C57BL/6N-TgH(Tnc), B6-TN, TNKO C57BL/6N-TgH(Tnc), B6-TN, TNKO C（3〜6か月） B6.Cg-Tnc<tm1Sia>/Rbrc B6.Cg-Tnc<tm1Sia>/Rbrc In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Am. J. Pathol., 152, 1237-1245 (1998). J. Invest. Dermatol., 111, 930-935 (1998). Invest. Ophthalmol. Visual. Sci., 1071-1080 (1999). Homozygote x Homozygote Homozygous mutant mice are viable and fertile. Tenascin C knock-out mice. This strain is useful for studying the biological function of extracellular matrix tenascin C in vivo, especially in the field of tumor development, tumor metastasis, wound healing, tissue regeneration, angiogenesis, tissue interaction etc. The tenascin C deficient congenic strains were developed by successive backcrossing with A/J (RBRC00007), BALB/cA (RBRC00067), C57BL/6N (RBRC00169), C3H/HeN (RBRC00110) and GRS/A (RBRC00193). Congenic strains were developed by Dr. M. Kusakabe, Cell Biology Laboratory, Life Science Tsukuba Research Center, RIKEN since 1992. A lacZ gene and neomycin resistant cassette was transfered into TT2 ES cells to replace the exon 2, just before the translation initiation codon of the Tnc gene. This strain was backcrossed to C57BL/6N. 細胞外基質テネイシンの機能解析のためのテネシイン欠損マウス系統。C57BL/6NJcl系統は代表的な近交系。B6/NはB6/J よりも繁殖性が良好。創傷治癒の機構解析。細胞接着、細胞間相互作用。毛色は黒。 C (3-6 months) <a href="https://mus.brc.riken.jp/ja/wp-content/uploads/pdf/blc/00169_GB.pdf">Genetic Background</a> Saga Y et al. (1992)により作成されたテネイシン欠損マウスを元に開発されたテネイシン欠損コンジェニック系統の一つ。 Homozygote x HomozygoteHomozygous mutant mice are viable and fertile. TT2 [(C57BL/6NCrlj x CBA/JNCrlj)F1] RBRC00169 true Tnc(-/-)同士の兄妹交配。繁殖効率はA。実験群作出にはB6/N との交配必要。 繁殖効率はB. E. coli lacZ, mouse phosphoglycerate kinase promoter (PGK promoter), E. coli neo, mouse tenascin genomic DNA Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> RIKEN BRC RIKEN BRC 条件を付加する。<br>研究成果の公表にあたって寄託者の指定する文献を引用する。Am. J. Pathol., 152, 1237-1245 (1998). J. Invest. Dermatol., 111, 930-935 (1998). Invest. Ophthalmol. Visual. Sci., 1071-1080 (1999).